Lanvin Group Holdings Limited (LANV)
NYSE: LANV · Real-Time Price · USD
2.180
+0.070 (3.32%)
Mar 14, 2025, 4:00 PM EST - Market closed
Lanvin Group Employees
Lanvin Group Holdings had 2,637 employees as of December 31, 2023. The number of employees decreased by 850 or -24.38% compared to the previous year.
Employees
2,637
Change (1Y)
-850
Growth (1Y)
-24.38%
Revenue / Employee
$155,465
Profits / Employee
-$50,233
Market Cap
255.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2,637 | -850 | -24.38% |
| Dec 31, 2022 | 3,487 | - | - |
LANV News
- 10 days ago - PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage - Business Wire
- 14 days ago - Lanvin Group Holdings Limited (LANV) 2024 Sales/Trading Statement Call Transcript - Seeking Alpha
- 14 days ago - Lanvin Group Prioritizes Creative Renewal and Operational Agility Amid Evolving Luxury Landscape - PRNewsWire
- 26 days ago - Lanvin Group to Report 2024 Full-Year Preliminary Revenues on February 28, 2025 - PRNewsWire
- 2 months ago - Lanvin Group Announces Leadership and Board Changes to Accelerate Growth and Strategic Initiatives - PRNewsWire
- 2 months ago - PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia - Business Wire
- 4 months ago - Lanvin Group Holdings Limited to Hold Annual General Meeting on December 11, 2024 - PRNewsWire
- 6 months ago - PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada - Business Wire